Abstract Objective To study the clinical features of neuroblastoma (NB) and the factors influencing survival rate. Methods A total of 44 children with NB who were admitted from April 2016 to February 2020 were enrolled as research subjects. A retrospective analysis was performed on their medical data and follow-up data. Results The common clinical symptoms of these 44 children were fever (10/44, 23%), mass (9/44, 20%), abdominal pain (8/44, 18%), cough (7/44, 16%), pale complexion (3/44, 7%), claudication (2/44, 5%), and abnormal activity (2/44, 5%). According to the INSS stage, 2 children (4%) had stage I NB, 5 children (11%) had stage II NB, 5 children (11%) had stage III NB, and 32 children (73%) had stage IV NB. The mean follow-up time was (15.3±1.5) months, with a recurrence rate of 20% and an overall survival rate of 82%. Among the 44 children, 29 (66%) achieved event-free survival and 7 (16%) had survival with tumor. The univariate analysis showed that a pathological type of NB and an increase in serum neuron-specific enolase (NSE) decreased the overall survival rate of children with NB (P < 0.05). Conclusions The clinical symptoms of children with NB are not specific at the first visit. Fever, abdominal pain, and mass are common symptoms, and there is a high proportion of children in the advanced stage. The pathological type of NB and an increase in serum NSE may be associated with a reduction in the overall survival rate of children with NB.
Kandula S, Prabhu RS, Nanda R, et al. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma[J]. J Pediatr Hematol Oncol, 2015, 37(3):175-180.
[4]
Liang J, Tong P, Zhao W, et al. The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage[J]. Int J Mol Sci, 2014, 15(7):11220-11233.
[5]
Castel V, García-Miguel P, Cañete A, et al. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting[J]. Eur J Cancer, 1999, 35(4):606-611.
[6]
Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window:a pediatric oncology group study[J]. J Clin Oncol, 2004, 22(20):4119-4126.
[7]
Howlader N, Noone AM, Yu M, et al. Use of imputed population-based cancer registry data as a method of accounting for missing information:application to estrogen receptor status for breast cancer[J]. Am J Epidemiol, 2012, 176(4):347-356.
Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research:neuroblastoma[J]. Pediatr Blood Cancer, 2013, 60(6):985-993.
[10]
Suita S, Tajiri T, Sera Y, et al. The characteristics of mediastinal neuroblastoma[J]. Eur J Pediatr Surg, 2000, 10(6):353-359.
[11]
Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in stage 3 neuroblastoma:a report from the International Neuroblastoma Risk Group project[J]. Pediatr Blood Cancer, 2014, 61(11):1932-1939.
Iehara T, Hosoi H, Akazawa K, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening[J]. Br J Cancer, 2006, 94(10):1510-1515.
